Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Multi-center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Pediatric Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen
Conditions
Interventions
tacrolimus modified release (MR)
tacrolimus
Locations
5
United States
Atlanta, Georgia, United States
Indianapolis, Indiana, United States
New Orleans, Louisiana, United States
New York, New York, United States
Madison, Wisconsin, United States
Start Date
January 1, 2004
Primary Completion Date
October 1, 2008
Completion Date
October 1, 2008
Last Updated
October 17, 2013
NCT07233096
NCT06717919
NCT06899867
NCT05237583
NCT06682325
NCT06890234
Lead Sponsor
Astellas Pharma Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions